BioScrip (NASDAQ:BIOS) released its earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.04), Fidelity Earnings reports. The business had revenue of $191.52 million during the quarter, compared to the consensus estimate of $185.73 million.
Shares of BioScrip stock traded up $0.02 on Wednesday, reaching $2.90. 295,431 shares of the company were exchanged, compared to its average volume of 913,941. The stock has a 50-day moving average price of $2.55. The stock has a market capitalization of $359.24 million, a price-to-earnings ratio of -5.92 and a beta of 0.68. BioScrip has a 1-year low of $1.56 and a 1-year high of $4.14.
A number of brokerages have recently weighed in on BIOS. TheStreet cut Red Lion Hotels from a “c” rating to a “d+” rating in a research report on Wednesday, April 3rd. Barrington Research reiterated a “buy” rating and set a $4.00 price target on shares of BioScrip in a research report on Friday, May 3rd. Zacks Investment Research upgraded Hanmi Financial from a “sell” rating to a “hold” rating in a research report on Thursday, June 20th. Finally, BidaskClub upgraded WhiteHorse Finance from a “sell” rating to a “hold” rating in a research report on Thursday, July 18th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $4.60.
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.
See Also: Preferred Stock
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.